ELYM
Price:
$7.39
Market Cap:
$495.57M
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem The...[Read more]
Industry
Biotechnology
IPO Date
2021-08-10
Stock Exchange
NASDAQ
Ticker
ELYM
According to Eliem Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -47.03%. This represents a change of 465.11% compared to the average of -8.32% of the last 4 quarters.
The mean historical ROE of Eliem Therapeutics, Inc. over the last ten years is -33.61%. The current -47.03% ROE has changed 39.92% with respect to the historical average. Over the past ten years (40 quarters), ELYM's ROE was at its highest in in the June 2020 quarter at 0%. The ROE was at its lowest in in the December 2020 quarter at -68.91%.
Average
-33.61%
Median
-32.64%
Minimum
-53.37%
Maximum
-18.42%
Discovering the peaks and valleys of Eliem Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 189.70%
Maximum Annual ROE = -18.42%
Minimum Annual Increase = -46.79%
Minimum Annual ROE = -53.37%
Year | ROE | Change |
---|---|---|
2023 | -32.64% | -7.37% |
2022 | -35.24% | 24.08% |
2021 | -28.40% | -46.79% |
2020 | -53.37% | 189.70% |
The current ROE of Eliem Therapeutics, Inc. (ELYM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-32.09%
5-year avg
-33.61%
10-year avg
-33.61%
Eliem Therapeutics, Inc.’s ROE is greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than MediciNova, Inc. (-13.37%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Rezolute, Inc. (-60.90%), greater than HCW Biologics Inc. (-385.90%), greater than Molecular Partners AG (-33.08%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than Adagene Inc. (-63.48%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Pardes Biosciences, Inc. (-54.84%), greater than Shattuck Labs, Inc. (-68.65%), less than Champions Oncology, Inc. (1.48%), greater than Century Therapeutics, Inc. (-65.37%),
Company | ROE | Market cap |
---|---|---|
-21.96% | $77.28M | |
-13.37% | $103.00M | |
-36.89% | $1.03B | |
-62.74% | $287.77M | |
-122.97% | $46.68M | |
-60.90% | $240.80M | |
-385.90% | $26.62M | |
-33.08% | $182.90M | |
-83.65% | $54.85M | |
-63.48% | $115.55M | |
-47.31% | $250.26M | |
-54.72% | $30.44M | |
-23.13% | $108.71M | |
-54.84% | $135.19M | |
-68.65% | $167.05M | |
1.48% | $57.77M | |
-65.37% | $123.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Eliem Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Eliem Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Eliem Therapeutics, Inc.'s ROE?
How is the ROE calculated for Eliem Therapeutics, Inc. (ELYM)?
What is the highest ROE for Eliem Therapeutics, Inc. (ELYM)?
What is the 3-year average ROE for Eliem Therapeutics, Inc. (ELYM)?
What is the 5-year average ROE for Eliem Therapeutics, Inc. (ELYM)?
How does the current ROE for Eliem Therapeutics, Inc. (ELYM) compare to its historical average?